Esperion files new drug submissions in Canada for Nexletol and Nexlizet as a treatment for reducing bad cholesterol and ...
Esperion shares were up 13% to $3.16 after the company said it has filed New Drug Submissions to Health Canada for Nexletol and Nexlizet, non-statin medications that reduce low-density lipoprotein ...
Esperion (ESPR) has filed New Drug Submissions to Health Canada for NEXLETOL and NEXLIZET, once-daily, accessible, oral non-statin medications ...
A UCLA study has outlined a new framework that researchers say would improve the predictive power of genetics to determine ...
a class of drug that effectively reduces cholesterol. Guidelines for doctors do not recommend prescribing statins to diabetic patients unless they have high cholesterol levels. But the new ...
Overall, a 20% decrease in LDL cholesterol was seen. Participants reported that they would have found more information on drug interactions ... make statins unavailable to non-insured or indigent ...
A UCLA study has outlined a new framework that researchers say would improve predictive power of genetics to determine how well a patient would ...
A UCLA study has outlined a new framework that researchers say would improve predictive power ... Researchers analyzed how their genetic makeups impacted their response to four of the most commonly ...
Tony Gotto, from the Weill Cornell Medical College in New York ... candidates for statin therapy. So even though participants had what is currently considered to be normal cholesterol or LDL ...
Any medication comes with the risk of side effects—but experts reveal specific signs that suggest your medicine is making you ...
Women who have had a stroke may be less likely than men to take medications to prevent a second stroke, with Mexican American women reporting the highest rates of nonadherence, according to new ...
An analysis of more than 1,300 stroke survivors found that women were less likely than their male counterparts to take ...